Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Longfeng Zhang
ResearcherPublications, citations & collaboration network
Longfeng Zhang is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 67 works, 577 citations, an h-index of 15 and an i10-index of 20.
67
Works
577
Citations
15
h-index
20
i10-index
IDs:OpenAlex
How has Longfeng Zhang's publication output changed over time?
ScholarIQpublication output · 2019–2024
Output grew0% over the shown period — from 2 works in 2019 to 2 in 2024.
2
4
2
1
2
20192020202220232024
What are the most-cited papers on Longfeng Zhang?
ScholarIQmost cited works
Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China
Hongfu Cai, Longfeng Zhang, Na Li, Shen Chen, Bin Zheng, Jing Yang, Lizhu Weng, Mao-Bai Liu
Clinical Therapeutics. 201951 Citations
Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis
Hongfu Cai, Longfeng Zhang, Na Li, Bin Zheng, Maobai Liu
Journal of Comparative Effectiveness Research. 202041 Citations
Wogonin inhibits in vitro herpes simplex virus type 1 and 2 infection by modulating cellular NF-κB and MAPK pathways
Ying Chu, Xiaowen Lv, Longfeng Zhang, Xingli Fu, Siwei Song, Airong Su, Deyan Chen, Lianhong Xu, Yongfang Wang, Zhiwei Wu, Zhihua Yun
BMC Microbiology. 202041 CitationsOPEN ACCESS
Vimentin inhibits type I interferon production by disrupting the TBK1-IKKε-IRF3 axis
Hongyang Liu, Guangqiang Ye, Xiaohong Liu, Mengdi Xue, Qiongqiong Zhou, Longfeng Zhang, Kunli Zhang, Li Huang, Changjiang Weng
S169236886. 202241 CitationsOPEN ACCESS
First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
Longfeng Zhang, Yongfu Hang, Maobai Liu, Na Li, Hongfu Cai
Frontiers in Oncology. 202036 CitationsOPEN ACCESS
Related on ScholarIQ
Fujian Medical University
Institution
Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China
Paper
Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis
Paper
Wogonin inhibits in vitro herpes simplex virus type 1 and 2 infection by modulating cellular NF-κB and MAPK pathways
Paper
Vimentin inhibits type I interferon production by disrupting the TBK1-IKKε-IRF3 axis
Paper
First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
Paper